Company intelligence
Optheras A/S
About Optheras A/S
Optheras A/S was founded in 2022 and is part of T&W Medical A/S, former Widex group. Optheras' is founded by a team of urologist, regulatory experts, business executives and technology experts. Our mission is to increase the quality of life for patients living with bladder cancer, while supporting more efficient use of medical ressources. We are developing a new laser tool, that will change how this disease is handled.
Verified activity
Signals from Optheras A/S
8 published signals
Products & Services
Optheras A/S has completed the first batch of ATLAS single-use devices and is ready to begin its First-in-Human study.
Reported by Thomas Alkeskjold
Products & Services
Optheras A/S is accepted into the American Urological Association's flagship program for urology innovation, the Nexus Innovation Bootcamp 2026.
Reported by Thomas Alkeskjold
Presence & Recognition
Optheras A/S is selected into the MedTech Innovator Cohort 2026, top 4% among 1800+ applicants.
Reported by Thomas Alkeskjold
Legal & Regulatory
Optheras A/S is enrolled in the FDA's TAP program following its Breakthrough Device Designation.
Reported by Thomas Alkeskjold
Products & Services
Optheras A/S is co-sponsored by Pedersen et al. in the 2026 Journal of Urology RCT comparing laser coagulation to TURBT with long-term follow-up.
Reported by Thomas Alkeskjold
Products & Services
Optheras A/S completed and presented an in-vivo animal study at the American Urological Association meeting 2026 with Herlev og Gentofte Hospital in Denmark.
Reported by Thomas Alkeskjold
Products & Services
Optheras A/S is pushing forward ATLAS, the Automatic Targeting Laser Ablation System.
Reported by Thomas Alkeskjold
Presence & Recognition
Optheras A/S is attending LSI Europe 2026 in Barcelona.
Reported by Thomas Alkeskjold